Prothena | PRTA - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 171.09M 1.9M 2026-03
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Akebia Therapeutics USD 265.42M 199K 2025-12
ALKERMES USD 167.54M 1.08M 2026-06
Alnylam Pharmaceuticals USD 133.73M 290K 2026-06
Amgen USD 541M 1000K 2026-06
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Exelixis USD 248.88M 4.82M 2026-06
Immunic USD 120.38M 21.73M 2025-12
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
MacroGenics USD 63.56M 241K 2026-03
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 100.55M 50K 2026-06
Prothena USD 53.08M 756K 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06